MannKind Corporation to Hold 2024 Fourth Quarter and Full Year Financial Results Conference Call on February 26, 2025

Rhea-AI Summary

MannKind (MNKD) has announced it will release its 2024 fourth quarter and full year financial results after market close on Wednesday, February 26, 2025. The company will host a webcast at 4:30 p.m. Eastern Time to discuss the financial results and provide a business update.

The conference call will feature CEO Michael Castagna and CFO Chris Prentiss. Investors can access the webcast through MannKind's website, and a replay will be available for approximately 90 days following the call.

News Market Reaction – MNKD

+2.72%

1 alert

+2.72% News Effect

On the day this news was published, MNKD gained 2.72%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Feb. 19, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), will release its 2024 fourth quarter and full year financial results after market close on Wednesday, February 26, 2025.

MannKind will host a webcast beginning at 4:30 p.m. Eastern Time to discuss the financial results and provide a business update. Participating in the conference call from MannKind will be Chief Executive Officer Michael Castagna, PharmD, and Chief Financial Officer Chris Prentiss. The webcast will be accessible via a link on MannKind’s website at https://investors.mannkindcorp.com/events-and-presentations. A replay will also be available in the same location within 24 hours following the call and be accessible for approximately 90 days.

About MannKind
MannKind Corporation (Nasdaq: MNKD) focuses on the development and commercialization of innovative inhaled therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases.

We are committed to using our formulation capabilities and device engineering prowess to lessen the burden of diseases such as diabetes, nontuberculous mycobacterial (NTM) lung disease, pulmonary fibrosis, and pulmonary hypertension. Our signature technologies – dry-powder formulations and inhalation devices – offer rapid and convenient delivery of medicines to the deep lung where they can exert an effect locally or enter the systemic circulation, depending on the target indication.

With a passionate team of Mannitarians collaborating nationwide, we are on a mission to give people control of their health and the freedom to live life.

Please visit mannkindcorp.com to learn more, and follow us on LinkedIn, Facebook, X or Instagram.

For MannKind:
Investor Relations
Ana Kapor
(818) 661-5000
Email: ir@mnkd.com

Media Relations
Christie Iacangelo
(818) 292-3500
Email: media@mnkd.com

FAQ

When will MannKind (MNKD) release its Q4 and full-year 2024 earnings?

MannKind will release its Q4 and full-year 2024 financial results after market close on Wednesday, February 26, 2025.

What time is MannKind's (MNKD) Q4 2024 earnings call?

MannKind's Q4 2024 earnings call will begin at 4:30 p.m. Eastern Time on February 26, 2025.

Who will participate in MannKind's (MNKD) Q4 2024 earnings call?

CEO Michael Castagna and CFO Chris Prentiss will participate in the earnings call.

How long will MannKind's (MNKD) Q4 2024 earnings call replay be available?

The earnings call replay will be available for approximately 90 days following the call on MannKind's investor relations website.